CN111372606B - 增强atp释放作用 - Google Patents

增强atp释放作用 Download PDF

Info

Publication number
CN111372606B
CN111372606B CN201880070859.6A CN201880070859A CN111372606B CN 111372606 B CN111372606 B CN 111372606B CN 201880070859 A CN201880070859 A CN 201880070859A CN 111372606 B CN111372606 B CN 111372606B
Authority
CN
China
Prior art keywords
ser
leu
gly
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880070859.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372606A (zh
Inventor
S·尚特克斯
N·戈尔丁
C·帕图雷
I·普罗特
B·罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Outrigger Biotechnology
Innate Pharma SA
Original Assignee
Outrigger Biotechnology
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Outrigger Biotechnology, Innate Pharma SA filed Critical Outrigger Biotechnology
Publication of CN111372606A publication Critical patent/CN111372606A/zh
Application granted granted Critical
Publication of CN111372606B publication Critical patent/CN111372606B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880070859.6A 2017-11-15 2018-11-15 增强atp释放作用 Active CN111372606B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762586224P 2017-11-15 2017-11-15
US62/586,224 2017-11-15
US201862686149P 2018-06-18 2018-06-18
US62/686,149 2018-06-18
US201862733175P 2018-09-19 2018-09-19
US62/733,175 2018-09-19
PCT/EP2018/081364 WO2019096900A1 (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Publications (2)

Publication Number Publication Date
CN111372606A CN111372606A (zh) 2020-07-03
CN111372606B true CN111372606B (zh) 2024-02-20

Family

ID=64332078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070859.6A Active CN111372606B (zh) 2017-11-15 2018-11-15 增强atp释放作用

Country Status (11)

Country Link
US (1) US20190218304A1 (enExample)
EP (1) EP3710052A1 (enExample)
JP (1) JP7383609B2 (enExample)
KR (1) KR102781619B1 (enExample)
CN (1) CN111372606B (enExample)
AU (1) AU2018368541B2 (enExample)
BR (1) BR112020009655A8 (enExample)
CA (1) CA3075371A1 (enExample)
IL (1) IL273440A (enExample)
SG (1) SG11202002195YA (enExample)
WO (1) WO2019096900A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
MX2019010848A (es) 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
SG10202111869SA (en) 2017-07-31 2021-11-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3692068B1 (en) * 2017-10-06 2022-12-07 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
JP7368453B2 (ja) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
JP7500442B2 (ja) 2018-06-18 2024-06-17 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
KR102856075B1 (ko) 2020-07-17 2025-09-04 삼성전자주식회사 비휘발성 메모리 장치 및 그 동작 방법
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
KR20240156633A (ko) 2022-03-03 2024-10-30 아르커스 바이오사이언시즈 인코포레이티드 항-cd39 항체 및 이의 용도
CN119013304A (zh) * 2022-03-04 2024-11-22 翠舒拉治疗股份有限公司 在胃癌中使用抗人cd39抗体、抗人pd-1抗体和化疗的组合
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073845A1 (en) * 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
WO2017089334A1 (en) * 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2017157948A1 (en) * 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
WO2018167267A1 (en) * 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
CN113754768B (zh) * 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2016073845A1 (en) * 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
WO2017089334A1 (en) * 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) * 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
WO2018167267A1 (en) * 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice";Mickaël Michaud 等;《Science》;第334卷(第6062期);1576-1577 *
"CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression";Nathalie Bonnefoy 等;《Oncoimmunology》;第4卷(第5期);doi: 10.1080/2162402X.2014.1003015 *
"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity";Jeremy Bastid 等;《Cancer Immunol Res》;第3卷(第3期);254-265 *
"Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer";M O Nicoletto 等;《Gynecol Oncol》;第100卷(第2期);第322页讨论 *

Also Published As

Publication number Publication date
BR112020009655A8 (pt) 2023-03-21
JP2021502980A (ja) 2021-02-04
AU2018368541B2 (en) 2025-06-12
EP3710052A1 (en) 2020-09-23
US20190218304A1 (en) 2019-07-18
KR20200088811A (ko) 2020-07-23
IL273440A (en) 2020-05-31
SG11202002195YA (en) 2020-04-29
CA3075371A1 (en) 2019-05-23
KR102781619B1 (ko) 2025-03-14
WO2019096900A1 (en) 2019-05-23
BR112020009655A2 (pt) 2020-10-13
JP7383609B2 (ja) 2023-11-20
AU2018368541A1 (en) 2020-03-19
CN111372606A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
CN111372606B (zh) 增强atp释放作用
JP7308150B2 (ja) 癌を処置するための組成物及び方法
JP7274469B2 (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
EP3912681A1 (en) Anti-cd39 antibodies
CN112334486B (zh) 用于治疗癌症的组合物和方法
EA045378B1 (ru) Усиление эффекта от высвобождения аденозинтрифосфата (атф)
HK40040395B (zh) 用於治疗癌症的组合物和方法
EA044293B1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220811

Address after: Marseille France

Applicant after: INNATE PHARMA

Applicant after: Outrigger Biotechnology

Address before: Marseille France

Applicant before: INNATE PHARMA

GR01 Patent grant
GR01 Patent grant